EC Number |
Inhibitors |
Structure |
---|
4.6.1.12 | N-([4-[(4-amino-2-oxopyrimidin-1(2H)-yl)methyl]-1-naphthyl]methyl)benzamide |
1 mM, 59% inhibition |
|
4.6.1.12 | N-[4-[(6-aminopyridin-3-yl)amino]-3-methylbenzyl]-4-(trifluoromethyl)benzamide |
1 mM, 60% inhibition |
|
4.6.1.12 | EDTA |
5 mM. Activity can be restored by the addition of Mg2+ to a concentration of 10 mM |
|
4.6.1.12 | more |
5-(1,3-benzodioxol-5-ylamino)-5-oxopentanoic acid, 2-[(2,6-diaminopyrimidin-4-yl)sulfanyl]acetamide and 4-(5-amino-1,3,4-oxadiazol-2-yl)-1,2,5-oxadiazol-3-amine are inactive. Activity with compounds 2-amino-N-hydroxy-acetimidic acid, N-hydroxy-nicotinimidic acid, 5-bromo-thiophene-2-sulfonic acid amide, 4-bromobenzenesulfonamide and 4-(4-dimethylamino-phenylazo)-benzenesulfonamide are not measurable |
|
4.6.1.12 | 2-amino-N-hydroxy-3-(1-H-indol-3-yl)-propionimidic acid |
highest affinity of all the ligands examined, due to Zn2+-hydroxamate coordination, KD value of 0.0019 mM |
|
4.6.1.12 | 4-amino-1-[(4aR,6R,7R,7aS)-2,7-dihydroxy-2-oxidotetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-6-yl]pyrimidin-2(1H)-one |
KD value of 0.925 mM |
|
4.6.1.12 | Cytosine arabinoside monophosphate |
KD value of 18.91 mM |
|
4.6.1.12 | 5-fluorocytidine |
KD value of 2.02 mM |
|
4.6.1.12 | 4-amino-1-[(2S,3aS,4S,6R,6aR)-2-hydroxy-6-(hydroxymethyl)-2-oxidotetrahydrofuro[3,4-d][1,3,2]dioxaphosphol-4-yl]pyrimidin-2(1H)-one |
KD value of 20.5 mM |
|
4.6.1.12 | Cidofovir |
KD value of ca. 40 mM |
|